Continuing Progress in the Interdisciplinary Management of Peritoneal Metastases

aDepartment of Surgery, Campus Charité Mitte/Campus Virchow Klinikum CCM/CVK, Berlin, Germany; bDepartment of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon, Lyon, France; cProgram in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC, USA; dDepartment of Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; eDivision of Surgical Oncology, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA; fRegional Cancer Therapies, Peritoneal Surface Metastasis Center, Kishiwada Tokushukai Hospital, Kishiwada, Japan; gAsian School of Peritoneal Surface Malignancy Treatment, Osaka, Japan; hDepartment of Surgery, Peritonectomy Unit, St George Hospital & University of New South Wales, Kogarah, NSW, Australia; iDepartment of Hematology, Oncology, and Cancer Immunology (CCM), Charité – Universitaetsmedizin Berlin, Berlin, Germany; jMassachusetts General Hospital Cancer Center, Boston, MA, USA; kHarvard Medical School, Boston, MA, USA Received: February 15, 2022 Accepted: February 22, 2022 Published online: March 8, 2022